SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Gliatech (GLIA)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: scaram(o)uche who wrote (600)2/4/1999 1:44:00 PM
From: lrb  Read Replies (1) of 2001
 
Anyone,
I posted the following on yahoo! since that thread seems more active, but will
be grateful for a response here or there:

I recall at the time of the advisory committee's recommendation of approval for
Adcon-L, there was no question that Adcon-L reduced scarring, but some disagreement
about the claim that reduced scarring improved patient outcome. Was the
just-released study required by the FDA in order for GLIA to continue selling Adcon-L?

Is there a similar issue with pelvic surgery and scarring? Is scarring
as common as it is in back surgery, and is it known to cause problems for the
patient? What size market would Adcon-P address, as compared with Adcon-L?
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News